Abstract Details

Title Risk of Rebound in Multiple Sclerosis after a Switch from Natalizumab to Fingolimod. Early Onset versus Delayed Onset.

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 291

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Rocio Hernandez Clares, MD, PhD (Virgen De La Arrixaca Hospital) PRESENTER	No disclosure on file
Ruben Carrasco Torres	No disclosure on file
Philip Scheltens, MD, PhD, FAAN (Alzheimer Center Amsterdam University medical Center)	Dr. Scheltens has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVO NOrdisk.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��